EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 160 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours MOST POPULAR Adagrasib Shows Promising Activity as Monotherapy, Even Greater in Combination with... January 11, 2023 Nous-209 Efficiently Stimulates Immunity Against Neoantigens in Lynch Syndrome Carriers February 3, 2026 Maintenance Rucaparib for Platinum-Sensitive Pancreatic Adenocarcinoma with HRD-Associated Mutations May 17, 2021 EMA Recommends Extension of Indications for Ribociclib to Include Use in... November 5, 2024 Load more HOT NEWS Man Who Lost His Mother to Breast Cancer Opens Resource Center... How to Maintain Your Sexual Health During and After Lung Cancer Promising Results Demostrated with Novel Subcutaneously Adminstered Envafolimab in Patients with... Camonsertib in Patients with Advanced Solid Tumours Harbouring Loss of Function...
